PRGO logo

PERRIGO CO PLC

PRGONYSE
πŸ† #1955 by market capUS Equity
$503.82β–Ό $25.09 (βˆ’4.98%)
Simulated price
πŸ””
Track PRGO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.09B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.8%
Declining
πŸ“ŠGross Margin
33.3%
Moderate
πŸ’΅FCF Margin
4.2%
Moderate
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
92
Very Good
No chart data available for PRGO.

Trading Snapshot

Day Range
$501.94 – $511.42
52-Week Range
$9.23 – $22.65
Volume
$2.00B
Avg Volume
$1.35B
Shares Outstanding
138.4M
Next Earnings
Nov 13, 2026

Fundamentals Snapshot

Annual Revenue
$4.25B
Last Q Revenue
$1.02B
P/E Ratio
-1.2
P/S Ratio
0.5x
EPS (TTM)
$-12.47
Dividend Yield
7.68%
Dilution (1yr)
+0.7%

Why Investors Own PRGO

  • βœ“High-growth profile β€” revenue up +53.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 79% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRGO logo

PERRIGO CO PLC

PRGO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.3Bβ–Ό βˆ’2.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.1%β–Ό βˆ’0.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$343Mβ–² +204.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$145Mβ–Ό βˆ’40.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
138.5Mβ–² +0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$3.4Bβ–Ό βˆ’$378M YoY
StockOtter Β· stockotter.space

About PERRIGO CO PLC

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Price Target

β“˜
Average Target
$505.37
β–² +0.3% Upside
High Target$633.11
Low Target$440.77
Based on 12 analysts

Latest News & Updates